Flubendazol
FLUBENDAZOL · Flubendazole Polymorph B · R-17899 · R 17889 · FLUMOXAL · FLUBENOL · FLUVERNAL · FLUMOXANE
Identifikatoren & physikalische Daten
| CAS No. | 31430-15-6 |
|---|---|
| Summenformel | C16H12FN3O3 |
| Durchschnittliche Molmasse | 313,28 g/mol |
| Monoisotopische Masse | 313,08626942 g/mol |
| SMILES | COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1 |
| InChIKey | CPEUVMUXAHMANV-UHFFFAOYSA-N |
| PubChem CID | 35802 |
| ChEMBL | CHEMBL1454946 |
| ChEBI | CHEBI:77095 |
| EC No. | 250-624-4 |
| DTXSID | DTXSID8023058 |
| Lokaler Name | Flubendazol |
Chemische & physikalische Eigenschaften
| XLogP | 2,9 |
|---|---|
| Polarare Oberfläche (TPSA) | 84,1 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 5 |
| Frei drehbare Bindungen | 4 |
| Schwere Atome | 23 |
| Formalladung | 0 |
| Komplexität | 454 |
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Antiparasitic products, insecticides and repellents -> Antiprotozoals |
| Animal Drugs | Pharmaceuticals -> UK Veterinary Medicines Directorate ListPharmaceuticals -> Animal Drugs -> Approved in Taiwan |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Schmelzpunkt | > 260290°C |
| Collision Cross Section | 177.36 Ų [M-H]- |
| Dichte | 1.3720 (estimate) |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | Practically insoluble in water, in alcohol and in methylene chloride |
| pKa (Säurekonstante) | 10.66±0.10(Predicted) |
| Aggregatzustand | Solid |
| Farbe | White to Off-White |
| Merck | 14,4118 |
| Hauptanwendungen | forensics and toxicologypharmaceutical (small molecule) |
| InChI | 1S/C16H12FN3O3/c1-23-16(22)20-15-18-12-7-4-10(8-13(12)19-15)14(21)9-2-5-11(17)6-3-9/h2-8H,1H3,(H2,18,19,20,22) |
| InChIKey | CPEUVMUXAHMANV-UHFFFAOYSA-N |
| SMILES | COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c3ccc(F)cc3 |
| CAS Datenbank | 31430-15-6(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 23.8% (5 of 21) of reports.WarningH361 (66.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 21 reports by companies from 7 notifications to the ECHA C&L Inventory. |
|---|---|
| Regulatorische Informationen | Flubendazole: Does not have an individual approval but may be used under an appropriate group standard |
| Weitere Sicherheitsinformationen | IMAP assessments - Carbamic acid, [5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]-,methyl ester: Environment tier I assessment |
| Hazard Classes and Categories | Repr. 2 (66.7%) |
| Wassergefährdungsklasse (WGK) | 2 |
| Zollcode | 29339900 |
| RTECS-Nr. | DD6497500 |
| R-Sätze (R) | 22 |
| Toxizität | LD50 in mice, rats, guinea pigs (mg/kg): >2560 orally (Thienpont) |
| Sicherheitshinweise (S) | 44 |
| Lagerklasse | 10 - Combustible liquids |
Anwendungen & Verwendung
Beschreibung
Flubendazole is a benzimidazole carbamate anthelmintic. It completely eliminates larvae in a mouse model of A. cantonensis infection and exhibits a mean larval reduction of 100% in a T. spiralis infection model when administered at doses of 5 and 50 mg/kg per day, respectively. Flubendazole inhibits mammalian tubulin polymerization (IC50 = 2.5 μM) and inhibits binding of [3H]mebendazole to H. contortus L3 larval tubulin (IC50 = 0.17 μM). Flubendazole also inhibits the proliferation of BT-549, SK-BR-3, MDA-MB-231, and MCF-7 breast cancer cells (IC50s = 0.72, 1.51, 1.75, and 5.51 μM, respectively) and reduces tumor growth in an MDA-MB-231 mouse xenograft model when administered at a dose of 25 mg/kg.
Verwenden
An anthelmintic.